Why the study?
Does ANGPTL8 blockade with REGN3776 reduce plasma triglycerides and body weight in mice and monkeys?
Population
Humanized ANGPTL8 mice and dyslipidemic cynomolgus monkeys
Design
Preclinical
Authors
Loading...
Hypothesis-generating for ANGPTL8 blockade in dyslipidemia; human trials needed before clinical consideration.
Does ANGPTL8 blockade with REGN3776 reduce plasma triglycerides and body weight in mice and monkeys?
Blockade of ANGPTL8 with a monoclonal antibody reduces plasma triglycerides and body weight in preclinical models, suggesting a potential therapeutic avenue for dyslipidemia.
Gusarova et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: